Lumos Pharma, Inc. (LUMO) earnings
LUMO earnings moved a median of +1.63% by the close. Quarterly and annual LUMO reports and results, each read against the price at its own news timestamp. Back to the LUMO overview →
11 measured LUMO earnings events.
Where these LUMO earnings landedvs 11 measured LUMO earnings reactions
| Middle 50% of LUMO earnings reactions | -4.29% to +1.92% |
|---|---|
| Median reaction (to close) | +1.63% |
| Measured reactions | 11 |
Point-in-time · zero look-ahead
Half of the 11 LUMO earnings events with a measured close landed between -4.29% and +1.92%; 64% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q LUMOS PHARMA, INC. For: Sep 30 | SEC filing · Form 10-Q | — | +0.35% | |
| Form 10-Q LUMOS PHARMA, INC. For: Jun 30 | SEC filing · Form 10-Q | -4.89% | +1.63% | |
| Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update | Press release | -4.89% | +1.63% | |
| Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024 | Press release | — | +2.61% | |
| Form 10-Q LUMOS PHARMA, INC. For: Mar 31 | SEC filing · Form 10-Q | +1.03% | +18.47% | |
| Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results | Press release | +0.00% | -8.57% | |
| Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024 | Press release | -0.17% | +0.00% | |
| Form 10-K/A LUMOS PHARMA, INC. For: Dec 31 | SEC filing · Form 10-K | -0.73% | +1.82% | |
| Form 10-K LUMOS PHARMA, INC. For: Dec 31 | SEC filing · Form 10-K | +0.69% | +2.01% | |
| Form 10-Q LUMOS PHARMA, INC. For: Sep 30 | SEC filing · Form 10-Q | -4.34% | -9.44% | |
| Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates | Press release | -4.34% | -9.44% |
Keep exploring
More LUMO: analyst actions → · SEC filings → · LUMO overview →